David Ross

50PUBLICATIONS
224CO-AUTHORS
PharmacogenomicsHaematological tumoursGene and molecular therapyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Oct 13, 2026
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.

|May 08, 2026
Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

|Apr 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

|Mar 05, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Barbara Mora, Francesca Palandri, Paola Guglielmelli

|Feb 27, 2026
Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia.

Harinder Gill, Francesca Palandri, David M Ross

|Sep 27, 2025
Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities.

Molly Tolland, David M Ross, Deborah White

Pageof 9

Frequent Collaborators

8 joint publications

Naranie Shanmuganathan

7 joint publications

Susan Branford

6 joint publications

Alessandro Maria Vannucchi

6 joint publications

Anna L Brown